Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies
T cells modified via chimeric antigen receptors (CARs) have emerged as a promising treatment modality. Unparalleled clinical efficacy recently demonstrated in refractory B-cell malignancy has brought this new form of adoptive immunotherapy to the center stage. Nonetheless, its current success has al...
Saved in:
Main Authors: | Shangjun Sun, He Hao, Ge Yang, Yi Zhang, Yang Fu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | Journal of Immunology Research |
Online Access: | http://dx.doi.org/10.1155/2018/2386187 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
by: Dingtian Luo, et al.
Published: (2025-02-01) -
Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases
by: Yuehong Chen, et al.
Published: (2019-01-01) -
Modified CD15/CD16-CLL1 inhibitory CAR-T cells for mitigating granulocytopenia toxicities in the treatment of acute myeloid leukemia
by: Rui Zhang, et al.
Published: (2025-02-01) -
Advancements in cellular immunotherapy: overcoming resistance in lung and colorectal cancer
by: Lijuan Qin, et al.
Published: (2025-02-01) -
ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma
by: Saffron E. Summers, et al.
Published: (2023-03-01)